References
- O'Keefe JH, Bhatti SK, Bajwa A, DiNicolantonio JJ, Lavie CJ, O'Keefe JH, et al. Alcohol and cardiovascular health: the dose makes the poison or the remedy. Mayo Clin Proc 2014;89:382–93.
- Report on Alcohol and Health. Geneva, Switzerland: World Health Organization; 2014.
- Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009;373:2223–33.
- Juel K, Sorensen J, Bronnum-Hansen H. Risk factors and public health in Denmark. Scand J Public Health 2008;36:11–227.
- Eliasen M, Becker U, Gronbaek M, Juel K, Tolstrup JS. Alcohol-attributable and alcohol-preventable mortality in Denmark: an analysis of which intake levels contribute most to alcohol's harmful and beneficial effects. Eur J Epidemiol 2014;29:15–26.
- Mitchell AJ, Meader N, Bird V, Rizzo M. Clinical recognition and recording of alcohol disorders by clinicians in primary and secondary care: meta-analysis. Br J Psychiatry 2012;201:93–100.
- Cohen E, Feinn R, Arias A, Kranzler HR. Alcohol treatment utilization: findings from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend 2007;86:214–22.
- Connor JP, Haber PS, Hall WD. Alcohol use disorders. Lancet 2016;387:988–98.
- Vilsboll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003;114:115–21.
- Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci 2012;32:4812–20.
- Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999;403:261–80.
- Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci1992;13:177–84.
- Egecioglu E, Steensland P, Fredriksson I, Feltmann K, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 2013;38:1259–70.
- Shirazi RH, Dickson SL, Skibicka KP. Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. PLoS One 2013;8:e61965.
- Suchankova P, Yan J, Schwandt ML, Stangl BL, Caparelli EC, Momenan R, et al. The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. Transl Psychiatry 2015;5:e583.
- Vallöf D, Maccioni P, Colombo G, Mandrapa M, Jörnulf JW, Egecioglu E, et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol 2016;21:422–37.